Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
-2.52%
+3.51%
+210.53%
+1.67%
ARVN
Arvinas
$9.32
Login to see Arvinas (ARVN) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid Strengths
Expands stock buyback program
Chart
$7.81 (+19.33%)
$7.59 (+22.79%)
$6.49 (+43.61%)
$26.57 (-64.92%)
ARVN has Moderate Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
Beta greater than 1.0
ARVN overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Reported a weak earnings
Below analyst estimate
Rating
Rating
Momentum
Momentum
Activity
Activity
Expands stock buyback program
Future
Future
ARVN Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
ARVN Street view is extremely bullish and have negative views on the near-term outlook
Average key support and resistance price levels.
Login to displayARVN Earnings
The TTM reflects 12-month period, providing review of ARVN financial performance.
The company financial health has shown minor improvement, but significant issues remain
Financial Score
PFE
26.25
-0.66%
XNCR
12.04
+1.91%
SNY
49.20
-1.04%
NVS
131.55
-0.54%
MRUS
94.39
+0.13%
What is ARVN current stock price?
What are ARVN stock strengths?
What risks are associated with ARVN stock?
When is ARVN next earnings report?
What is ARVN market cap and volume?
What is ARVN's current Stock IQ?
Should I buy ARVN stock right now?
Is ARVN a Strong Buy right now?
What does a 'Strong Buy' rating mean for ARVN?
What does a 'Strong Sell' rating mean for ARVN?
What factors influence ARVN's Stock IQ?
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-2.52%
+3.51%
+210.53%
+1.67%
ARVN
Arvinas
Current Price
$9.32
Stock Insights
Strengths
Expands stock buyback program
Linked to ARVN
PFE
26.25
-0.66%
XNCR
12.04
+1.91%
SNY
49.20
-1.04%
NVS
131.55
-0.54%
MRUS
94.39
+0.13%
Login to unlock Arvinas (ARVN) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid
Chart
$7.81 (+19.33%)
$7.59 (+22.79%)
$6.49 (+43.61%)
$26.57 (-64.92%)
ARVN Analysts Opinion
ARVN Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Reported a weak earnings
Below analyst estimate
Rating
Rating
Momentum
Momentum
Activity
Activity
Expands stock buyback program
Future
Future
ARVN Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
ARVN Street view is extremely bullish and have negative views on the near-term outlook
ARVN has Moderate Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
Beta greater than 1.0
Average key support and resistance price levels.
Login to displayARVN Earnings
The TTM data reflects the most recent 12-month period, providing overview of ARVN financial performance.
ARVN Financial Health
The company financial health has shown minor improvement, but significant issues remain
Financial Score
ARVN Latest Analysis
Arvinas to Present Clinical Data for ARV-102 a PROTAC LRRK2 Degrader at the 2025 International Congress of Parkinsons Disease and Movement Disorders®. NEW HAVEN Conn. Oct. 01 2025 (GLOBE NEWSWIRE) -- Arvinas Inc. (NASDAQ:) a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation today announced that two presentations including one e-poster session and one oral platform presentation featuring clinical data for ARV-102 an investigational oral PROTA
Wed Oct 1, 2025
Arvinas To Cut Jobs Out-License Vepdegestrant And Launch $100 Mln Stock Buyback Plan . (RTTNews) - Arvinas Inc. (ARVN) and Pfizer Inc. (PFE) announced plans to jointly select a third party for the out-licensing and commercialization of vepdegestrant. As part of its operational streamlining Arvinas will reduce its workforce by an additional 15% with the most signi
Thu Sep 18, 2025
Arvinas announces $100M share repurchase program.
Thu Sep 18, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
ARVN Stock trends
ARVN Stock performance
ARVN Stock analysis
ARVN investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings